Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Beyond the MHC: A canine model of dermatomyositis shows a complex pattern of genetic risk involving novel loci.

Evans JM, Noorai RE, Tsai KL, Starr-Moss AN, Hill CM, Anderson KJ, Famula TR, Clark LA.

PLoS Genet. 2017 Feb 3;13(2):e1006604. doi: 10.1371/journal.pgen.1006604.

2.

Gene Expression Profiling in Blood and Affected Muscle Tissues Reveals Differential Activation Pathways in Patients with New-onset Juvenile and Adult Dermatomyositis.

López De Padilla CM, Crowson CS, Hein MS, Pendegraft RS, Strausbauch MA, Niewold TB, Ernste FC, Peterson E, Baechler EC, Reed AM.

J Rheumatol. 2017 Jan;44(1):117-124. doi: 10.3899/jrheum.160293.

PMID:
27803134
3.

Consensus-based recommendations for the management of juvenile dermatomyositis.

Enders FB, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, Lahdenne P, Magnusson B, Nistala K, Ozen S, Pilkington C, Ravelli A, Russo R, Uziel Y, van Brussel M, van der Net J, Vastert S, Wedderburn LR, Wulffraat N, McCann LJ, van Royen-Kerkhof A.

Ann Rheum Dis. 2017 Feb;76(2):329-340. doi: 10.1136/annrheumdis-2016-209247.

4.

The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes.

Rider LG, Nistala K.

J Intern Med. 2016 Jul;280(1):24-38. doi: 10.1111/joim.12444.

PMID:
27028907
6.

Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics.

Moghadam-Kia S, Oddis CV, Aggarwal R.

Clin Rev Allergy Immunol. 2017 Feb;52(1):81-87. doi: 10.1007/s12016-016-8530-2. Review.

7.

Gene Expression Profiles from Disease Discordant Twins Suggest Shared Antiviral Pathways and Viral Exposures among Multiple Systemic Autoimmune Diseases.

Gan L, O'Hanlon TP, Lai Z, Fannin R, Weller ML, Rider LG, Chiorini JA, Miller FW.

PLoS One. 2015 Nov 10;10(11):e0142486. doi: 10.1371/journal.pone.0142486.

8.

Treatment of inflammatory myopathy: emerging therapies and therapeutic targets.

Moghadam-Kia S, Aggarwal R, Oddis CV.

Expert Rev Clin Immunol. 2015;11(11):1265-75. doi: 10.1586/1744666X.2015.1082908. Review.

9.

Scanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory Myopathies.

De Paepe B, Zschüntzsch J.

Int J Mol Sci. 2015 Aug 11;16(8):18683-713. doi: 10.3390/ijms160818683. Review.

10.

Peripheral Blood Cells from Patients with Autoimmune Addison's Disease Poorly Respond to Interferons In Vitro, Despite Elevated Serum Levels of Interferon-Inducible Chemokines.

Edvardsen K, Bjånesøy T, Hellesen A, Breivik L, Bakke M, Husebye ES, Bratland E.

J Interferon Cytokine Res. 2015 Oct;35(10):759-70. doi: 10.1089/jir.2014.0171.

11.

Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research.

Rider LG, Dankó K, Miller FW.

Curr Opin Rheumatol. 2014 Nov;26(6):724-41. doi: 10.1097/BOR.0000000000000119. Review.

12.

Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications.

Moran EM, Mastaglia FL.

Clin Exp Immunol. 2014 Dec;178(3):405-15. doi: 10.1111/cei.12445. Review.

13.

Idiopathic inflammatory myopathies.

Dimachkie MM, Barohn RJ, Amato AA.

Neurol Clin. 2014 Aug;32(3):595-628, vii. doi: 10.1016/j.ncl.2014.04.007. Review.

14.

Increased levels of eotaxin and MCP-1 in juvenile dermatomyositis median 16.8 years after disease onset; associations with disease activity, duration and organ damage.

Sanner H, Schwartz T, Flatø B, Vistnes M, Christensen G, Sjaastad I.

PLoS One. 2014 Mar 19;9(3):e92171. doi: 10.1371/journal.pone.0092171.

15.

Twins discordant for myositis and systemic lupus erythematosus show markedly enriched autoantibodies in the affected twin supporting environmental influences in pathogenesis.

Gan L, O'Hanlon TP, Gordon AS, Rider LG, Miller FW, Burbelo PD.

BMC Musculoskelet Disord. 2014 Mar 6;15:67. doi: 10.1186/1471-2474-15-67.

16.

Preferential infiltration of interleukin-4-producing CXCR4+ T cells in the lesional muscle but not skin of patients with dermatomyositis.

Fujiyama T, Ito T, Ogawa N, Suda T, Tokura Y, Hashizume H.

Clin Exp Immunol. 2014 Jul;177(1):110-20. doi: 10.1111/cei.12311.

17.

Suppression of soluble T cell-associated proteins by an anti-interferon-α monoclonal antibody in adult patients with dermatomyositis or polymyositis.

Guo X, Higgs BW, Rebelatto M, Zhu W, Greth W, Yao Y, Roskos LK, White WI.

Rheumatology (Oxford). 2014 Apr;53(4):686-95. doi: 10.1093/rheumatology/ket413.

18.

Correlation between the frequency of Th17 cell and the expression of microRNA-206 in patients with dermatomyositis.

Tang X, Tian X, Zhang Y, Wu W, Tian J, Rui K, Tong J, Lu L, Xu H, Wang S.

Clin Dev Immunol. 2013;2013:345347. doi: 10.1155/2013/345347.

19.

Myeloid related protein induces muscle derived inflammatory mediators in juvenile dermatomyositis.

Nistala K, Varsani H, Wittkowski H, Vogl T, Krol P, Shah V, Mamchaoui K, Brogan PA, Roth J, Wedderburn LR.

Arthritis Res Ther. 2013 Sep 23;15(5):R131. doi: 10.1186/ar4311.

20.

Role of the promoter polymorphism IL-6 -174G/C in dermatomyositis and systemic lupus erythematosus.

Hristova M, Dourmishev L, Kamenarska Z, Nikolova S, Kaneva R, Vinkov A, Baleva M, Monova D, Mitev V.

Biomed Res Int. 2013;2013:315365. doi: 10.1155/2013/315365.

Supplemental Content

Support Center